Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of rFVIIIFc 1000 vs 3000 IU Vials in Severe Hemophilia A
NCT02083965Phase 1Completed
- Sponsor
- Sanofi
- Start
- Mar 2014
- Primary completion
- Oct 2014
- Modality
- Fc-Fusion Proteins
- Countries
- 3
01
Overview
Phase 1, randomised, open-label trial of eftrenonacog alfa in hemophilia A (2 arms), sponsored by Sanofi. Primary endpoints: Area Under the Concentration-time Curve From Time Zero to Infinity at 96 hours and Incremental Recovery (K Value) at 96 hours. Started Mar 2014; status: completed.
02
Drugs
eftrenonacog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT02083965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02083965.